These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37149357)

  • 21. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
    Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
    Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus reactivation influences clonal evolution in human herpesvirus-8-related lymphoproliferative disorders.
    Granai M; Facchetti M; Mancini V; Goedhals J; Sherriff A; Mundo L; Bellan C; Amato T; Sorrentino E; Ungari M; Raphael M; Leoncini L; Facchetti F; Lazzi S
    Histopathology; 2021 Dec; 79(6):1099-1107. PubMed ID: 34431125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder.
    Pina-Oviedo S; Miranda RN; Medeiros LJ
    Am J Surg Pathol; 2018 Jan; 42(1):116-129. PubMed ID: 29112013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
    Latour S; Winter S
    Front Immunol; 2018; 9():1103. PubMed ID: 29942301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.
    Cohen JI; Kimura H; Nakamura S; Ko YH; Jaffe ES
    Ann Oncol; 2009 Sep; 20(9):1472-1482. PubMed ID: 19515747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
    Kato S; Miyata T; Takata K; Shimada S; Ito Y; Tomita A; Elsayed AA; Takahashi E; Asano N; Kinoshita T; Kimura H; Nakamura S
    Hum Pathol; 2013 Dec; 44(12):2849-52. PubMed ID: 24012167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related Epstein-Barr Virus-associated Lymphoproliferative Disorder Masquerading as Systemic Lupus Erythematosus.
    Kadoba K; Nishimura K; Uchino K; Waki D; Murabe H; Yokota T
    Intern Med; 2021 Aug; 60(15):2495-2497. PubMed ID: 33583902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
    Schwartz Z; Bowe RB; Coleman M; Magro CM
    Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency.
    Satou A; Nakamura S
    Cancer Med; 2021 Oct; 10(19):6777-6785. PubMed ID: 34387382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus-associated lymphomas decoded.
    Bednarska K; Chowdhury R; Tobin JWD; Swain F; Keane C; Boyle S; Khanna R; Gandhi MK
    Br J Haematol; 2024 Feb; 204(2):415-433. PubMed ID: 38155519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency.
    Bienemann K; Borkhardt A; Klapper W; Oschlies I
    Histopathology; 2015 Nov; 67(5):607-16. PubMed ID: 25728094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic mutations in
    Gao LM; Zhao S; Zhang WY; Wang M; Li HF; Lizaso A; Liu WP
    Cancer Biol Ther; 2019; 20(10):1319-1327. PubMed ID: 31311407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A look into the evolution of Epstein-Barr virus-induced lymphoproliferative disorders: a case study.
    Ambrosio MR; Rocca BJ; Ginori A; Mourmouras V; Amato T; Vindigni C; Lazzi S; Leoncini L
    Am J Clin Pathol; 2015 Nov; 144(5):817-22. PubMed ID: 26486748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-occurrence of EBV-positive classic Hodgkin lymphoma and B-cell lymphomas of different clonal origins: A case report and literature review.
    Karube K; Takatori M; Kohno K; Tomoyose T; Ohshiro K; Nakazato I
    Pathol Int; 2020 Nov; 70(11):893-898. PubMed ID: 32881147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder.
    Daroontum T; Kohno K; Inaguma Y; Okamoto A; Okamoto M; Kimura Y; Nagahama M; Sakakibara A; Satou A; Nakamura S
    Pathol Int; 2019 Jan; 69(1):37-41. PubMed ID: 30450620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis.
    Ishida M; Hodohara K; Yoshii M; Okuno H; Horinouchi A; Nakanishi R; Harada A; Iwai M; Yoshida K; Kagotani A; Yoshida T; Okabe H
    Int J Clin Exp Pathol; 2013; 6(10):2237-41. PubMed ID: 24133604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.
    Zheng M; Bao Y; Wang J; Ma Y; Yang Y; Zhang P; Chen L; Zheng K; Zhou J
    Hematol Oncol; 2022 Aug; 40(3):381-389. PubMed ID: 35405763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [EBV-associated lymphoproliferative disorders].
    Overkamp M; Quintanilla-Martinez L; Fend F
    Pathologie (Heidelb); 2022 Jul; 43(4):282-291. PubMed ID: 35925225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.
    Neparidze N; Lacy J
    Clin Adv Hematol Oncol; 2014 Jun; 12(6):358-71. PubMed ID: 25003566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.